493 related articles for article (PubMed ID: 33826819)
1. Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351.
Shen X; Tang H; Pajon R; Smith G; Glenn GM; Shi W; Korber B; Montefiori DC
N Engl J Med; 2021 Jun; 384(24):2352-2354. PubMed ID: 33826819
[No Abstract] [Full Text] [Related]
2. Susceptibility of Circulating SARS-CoV-2 Variants to Neutralization.
Wang GL; Wang ZY; Duan LJ; Meng QC; Jiang MD; Cao J; Yao L; Zhu KL; Cao WC; Ma MJ
N Engl J Med; 2021 Jun; 384(24):2354-2356. PubMed ID: 33822491
[No Abstract] [Full Text] [Related]
3. Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines.
Wang Y
EBioMedicine; 2021 Nov; 73():103677. PubMed ID: 34742128
[No Abstract] [Full Text] [Related]
4. Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine.
Wu K; Werner AP; Koch M; Choi A; Narayanan E; Stewart-Jones GBE; Colpitts T; Bennett H; Boyoglu-Barnum S; Shi W; Moliva JI; Sullivan NJ; Graham BS; Carfi A; Corbett KS; Seder RA; Edwards DK
N Engl J Med; 2021 Apr; 384(15):1468-1470. PubMed ID: 33730471
[No Abstract] [Full Text] [Related]
5. Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351).
Moyo-Gwete T; Madzivhandila M; Makhado Z; Ayres F; Mhlanga D; Oosthuysen B; Lambson BE; Kgagudi P; Tegally H; Iranzadeh A; Doolabh D; Tyers L; Chinhoyi LR; Mennen M; Skelem S; Marais G; Wibmer CK; Bhiman JN; Ueckermann V; Rossouw T; Boswell M; de Oliveira T; Williamson C; Burgers WA; Ntusi N; Morris L; Moore PL
N Engl J Med; 2021 Jun; 384(22):2161-2163. PubMed ID: 33826816
[No Abstract] [Full Text] [Related]
6. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.
Wang Z; Schmidt F; Weisblum Y; Muecksch F; Barnes CO; Finkin S; Schaefer-Babajew D; Cipolla M; Gaebler C; Lieberman JA; Oliveira TY; Yang Z; Abernathy ME; Huey-Tubman KE; Hurley A; Turroja M; West KA; Gordon K; Millard KG; Ramos V; Da Silva J; Xu J; Colbert RA; Patel R; Dizon J; Unson-O'Brien C; Shimeliovich I; Gazumyan A; Caskey M; Bjorkman PJ; Casellas R; Hatziioannou T; Bieniasz PD; Nussenzweig MC
Nature; 2021 Apr; 592(7855):616-622. PubMed ID: 33567448
[TBL] [Abstract][Full Text] [Related]
7. Neutralizing Activity of BNT162b2-Elicited Serum.
Liu Y; Liu J; Xia H; Zhang X; Fontes-Garfias CR; Swanson KA; Cai H; Sarkar R; Chen W; Cutler M; Cooper D; Weaver SC; Muik A; Sahin U; Jansen KU; Xie X; Dormitzer PR; Shi PY
N Engl J Med; 2021 Apr; 384(15):1466-1468. PubMed ID: 33684280
[No Abstract] [Full Text] [Related]
8. Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination.
Widge AT; Rouphael NG; Jackson LA; Anderson EJ; Roberts PC; Makhene M; Chappell JD; Denison MR; Stevens LJ; Pruijssers AJ; McDermott AB; Flach B; Lin BC; Doria-Rose NA; O'Dell S; Schmidt SD; Neuzil KM; Bennett H; Leav B; Makowski M; Albert J; Cross K; Edara VV; Floyd K; Suthar MS; Buchanan W; Luke CJ; Ledgerwood JE; Mascola JR; Graham BS; Beigel JH;
N Engl J Med; 2021 Jan; 384(1):80-82. PubMed ID: 33270381
[No Abstract] [Full Text] [Related]
9. SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people.
Narowski TM; Raphel K; Adams LE; Huang J; Vielot NA; Jadi R; de Silva AM; Baric RS; Lafleur JE; Premkumar L
Cell Rep; 2022 Feb; 38(5):110336. PubMed ID: 35090596
[TBL] [Abstract][Full Text] [Related]
10. Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac.
Chen Y; Shen H; Huang R; Tong X; Wu C
Lancet Infect Dis; 2021 Aug; 21(8):1071-1072. PubMed ID: 34051887
[No Abstract] [Full Text] [Related]
11. Robust neutralization of SARS-CoV-2 variants including JN.1 and BA.2.87.1 by trivalent XBB vaccine-induced antibodies.
Wang X; Jiang S; Ma W; Zhang Y; Wang P
Signal Transduct Target Ther; 2024 May; 9(1):123. PubMed ID: 38724561
[No Abstract] [Full Text] [Related]
12. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 IgG Levels as Predictors of XBB Variant Neutralization, Israel, 2022- and 2023.
Lustig Y; Canetti M; Indenbaum V; Peretz Y; Weiss-Ottolenghi Y; Margalit I; Asraf K; Levin T; Zuckerman N; Tomer E; Mandelboim M; Doolman R; Barda N; Regev-Yochay G
Emerg Infect Dis; 2024 May; 30(5):1050-1052. PubMed ID: 38666742
[TBL] [Abstract][Full Text] [Related]
14. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants.
Liu J; Liu Y; Xia H; Zou J; Weaver SC; Swanson KA; Cai H; Cutler M; Cooper D; Muik A; Jansen KU; Sahin U; Xie X; Dormitzer PR; Shi PY
Nature; 2021 Aug; 596(7871):273-275. PubMed ID: 34111888
[TBL] [Abstract][Full Text] [Related]
15. Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants.
Zani A; Caccuri F; Messali S; Bonfanti C; Caruso A
Emerg Microbes Infect; 2021 Dec; 10(1):1241-1243. PubMed ID: 34092181
[TBL] [Abstract][Full Text] [Related]
16. Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum.
Bates TA; Leier HC; Lyski ZL; McBride SK; Coulter FJ; Weinstein JB; Goodman JR; Lu Z; Siegel SAR; Sullivan P; Strnad M; Brunton AE; Lee DX; Adey AC; Bimber BN; O'Roak BJ; Curlin ME; Messer WB; Tafesse FG
Nat Commun; 2021 Aug; 12(1):5135. PubMed ID: 34446720
[TBL] [Abstract][Full Text] [Related]
17. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
Choi A; Koch M; Wu K; Dixon G; Oestreicher J; Legault H; Stewart-Jones GBE; Colpitts T; Pajon R; Bennett H; Carfi A; Edwards DK
J Virol; 2021 Nov; 95(23):e0131321. PubMed ID: 34549975
[TBL] [Abstract][Full Text] [Related]
18. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
[TBL] [Abstract][Full Text] [Related]
19. Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies.
Fernández J; Bruneau N; Fasce R; Martín HS; Balanda M; Bustos P; Ulloa S; Mora J; Ramírez E
J Med Virol; 2022 Jan; 94(1):399-403. PubMed ID: 34460119
[TBL] [Abstract][Full Text] [Related]
20. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
Elife; 2020 Oct; 9():. PubMed ID: 33112236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
